We're calling this a "quasi" guest post because
the author, Reed Smith's Dean Balaes, is actually trying out to join
our blogging team. This is his inaugural post, of what we hope will
be many more. This particular post addresses the causation aspects
of a case, Gayle v. Pfizer, Inc., ___ F. Supp.3d ___, 2020
WL 1685313 (S.D.N.Y. April 7, 2020), that we mentioned in
yesterday's preemption post. As we hope you'll see
shortly, the causation issues in Gayle are also interesting, and
favorable to the right side of the "v." Without further
ado, take it away Dean.
*******************
As is often the case in pharmaceutical product liability
actions, another group of plaintiffs' claims suffered a fatal
deficiency: establishing a causal association between the drug at
issue and the alleged injury. Gayle v. Pfizer, Inc., ___ F.
Supp.3d ___, No. 19-CV-3451, 2020 WL 1685313 (S.D.N.Y. April 7,
2020), illustrates this debilitating deficiency when the other side
alleged that
